BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15254165)

  • 1. Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen.
    Walters KA; Joyce MA; Addison WR; Fischer KP; Tyrrell DL
    J Virol; 2004 Aug; 78(15):7925-37. PubMed ID: 15254165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral and cellular determinants involved in hepadnaviral entry.
    Glebe D; Urban S
    World J Gastroenterol; 2007 Jan; 13(1):22-38. PubMed ID: 17206752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
    Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles.
    Pugh JC; Di Q; Mason WS; Simmons H
    J Virol; 1995 Aug; 69(8):4814-22. PubMed ID: 7609048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
    Miller DS; Kotlarski I; Jilbert AR
    Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
    Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
    J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
    Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
    J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes.
    Breiner KM; Urban S; Glass B; Schaller H
    J Virol; 2001 Jan; 75(1):143-50. PubMed ID: 11119583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of binding peptides on replication of duck hepatitis B virus].
    Jia HY; Chen Z; Zhou LF; Chen F; Zhu HH; Liu JH; Xu XY
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):116-20. PubMed ID: 15812883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duck hepatitis B virus (DHBV) infection in Indian domestic ducks: a pilot study.
    Sridhar G; Valliammai T; Varalakshmi CS; Udayasankar K; Panchanadam M; Ramakrishna J; Gopal KV; Jayaraman K; Thyagarajan SP
    Trop Anim Health Prod; 1993 Nov; 25(4):229-33. PubMed ID: 8109057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
    Miller DS; Halpern M; Kotlarski I; Jilbert AR
    Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
    Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the kinetics of the specific cellular immune response to duck hepatitis B virus in infected and immune ducks.
    Vickery K; Cossart Y; Dixon R
    Vet Microbiol; 1999 Aug; 68(1-2):157-69. PubMed ID: 10501173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
    Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
    J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHBV manipulation and prediction of the outcome of infection.
    Vickery K; Cossart Y
    J Hepatol; 1996 Oct; 25(4):504-9. PubMed ID: 8912150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
    Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
    Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duck hepatitis B virus infection of Muscovy duck hepatocytes and nature of virus resistance in vivo.
    Pugh JC; Simmons H
    J Virol; 1994 Apr; 68(4):2487-94. PubMed ID: 7511172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immune response of ducks to duck hepatitis B virus infection.
    Vickery K; Cossart Y; Dixon R
    J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].
    Chen XM; Liu ZM; Du XF; Yang ZG; Chen XM
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):121-5. PubMed ID: 15812884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.